Overview: AI cybersecurity uses machine learning and automation to detect threats in real time.Leading firms in the USA are ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...

Topline data were announced from a phase 3 trial evaluating valbenazine in pediatric and adult patients with dyskinetic cerebral palsy.

Zenas BioPharma (ZBIO) announce results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease. Obexelimab met the ...

The zero-day exploitations of Ivanti's MDM platform meant unprecedented pwning of 1000s of orgs by a Chinese APT — and ...

Jyong Biotech (MENS) announced that it has achieved another milestone in the development of its plant-derived new drug MCS-8, PCP. The Company has completed the statistical analysis of the primary ...

New Taipei City, Taiwan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to ...

The TULIP-SC trial evaluated the efficacy and safety of the subcutaneous administration of SAPHNELO compared to placebo in participants with moderately to severely active, autoantibody-positive SLE, ...

A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading. The study enrolled 30 ...